Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SI-B001 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Biokin Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**SI-B001 + paclitaxel** is a combination therapy comprised of SI-B001, a novel bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), and paclitaxel, a microtubule inhibitor. SI-B001 (also known as izalontamab) blocks both EGFR and HER3, key drivers in tumor proliferation, with demonstrated antitumor activity in EGFR-driven epithelial cancers. Paclitaxel disrupts cell division by stabilizing microtubules. This combination is primarily being investigated for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), especially after progression following anti-PD-1 immunotherapy and platinum-based chemotherapy. In phase II studies, this combination has shown improved objective response rate and disease control rate compared to SI-B001 monotherapy, with manageable toxicity[1][3][4].
- Other names
- izalontamab + paclitaxel
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SI-B001 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SI-B001 + paclitaxel.